Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
about
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesDipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative reviewOrigin and therapy for hypertriglyceridaemia in type 2 diabetesAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesGemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes MellitusCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisAssessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysisPractical combination therapy based on pathophysiology of type 2 diabetesDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsSaxagliptin overview: special focus on safety and adverse effectsDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetesPatients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.Emerging gliptins for type 2 diabetes.Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine.Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapyDipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment.Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.Linagliptin as add-on therapy to insulin for patients with type 2 diabetesEffects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
P2860
Q26765047-E78F6E13-B451-4B71-AEA2-BFE095304690Q26767260-91AA5302-26EB-4B9E-8A40-08E07BAF5BB9Q26824004-F896526F-0A94-4A8A-92E7-5162D7BEA5D2Q26827955-76065EF7-55E1-404A-A7D6-93B607E1952AQ28066209-7F340A40-D29D-420B-94FB-7C2950974E9BQ28071764-9272CD99-8602-4B4B-BFB0-19D266BCAC03Q28075335-673CAB92-0A1D-4036-98EF-B7D55601D7A8Q28076530-18F1805B-70CE-432C-A930-61CCFE81524FQ28238585-DD8A3E06-96F8-40B0-A33E-EA73ABE8C37CQ28278863-AC69916B-0BE8-433A-8671-307C0E361236Q28294225-96BCEED4-8D4B-4444-97EB-3068F55B635DQ30240823-0FC67A12-FA36-4F74-A05F-426BDBCF2498Q33412360-3EE22ED2-E6C4-478B-89C3-1D486A18FB6CQ33633710-CB96381A-AF5F-4E04-A516-FD591A1870B9Q33732627-C0613C55-537D-44D0-8BCE-E6E17D628910Q34081331-A81C84ED-0893-4169-B7EB-931C524352CEQ34154661-6B392AB9-9D54-4A59-B01F-957B6E1C2926Q34169097-1A0B49CF-CC51-4A63-9DE5-29A795DAA790Q34347884-70B62DCF-4000-41C2-ACD7-DBF8C4B58A86Q34454269-B64FDB71-6D6D-49AC-82EC-9D786A1EE91DQ34783302-7680B980-013B-40A3-A2E9-5B665A2B3787Q35236019-BB407AC4-B7D1-49E9-9012-A0C76BE53AF9Q35497064-7A0EEE8F-19B3-4D4F-8AD8-37CE0D139C0BQ35772593-9CE87EE4-4BFA-47D3-8B5D-A3520A6772FBQ35846876-0EB0FA37-A5C8-41B2-8EB1-61DB401597C4Q36327126-AA03FFAB-8CFB-468D-93EE-440C1078733EQ36360065-1BEE4BB6-911E-4A65-941D-A8055E3DC256Q36546914-00EB274A-3159-43B7-8EE9-F0D64902887AQ37072773-4AA61AA8-53AC-4CAE-8ECC-E06A855C01A8Q37101632-3A6054D4-506B-400A-9165-EBB768DDC30CQ37239303-293B28F9-DB79-4040-BE39-E0084C8CBA53Q37279276-A987D981-1DD8-47B0-BD66-A1A4A86CBBDCQ37281205-E9FDB6DD-058B-469D-AAF6-9741EFEA0107Q37331159-85423C7F-5902-453E-8F65-9F89591E3C5DQ37384190-CD99A5D4-1442-4398-BE25-97AAB7FC6D1DQ37427294-36B57461-4D2D-4D1F-A5F6-AABF4F3233FCQ37446672-3BD3B105-CC6E-499E-A818-C24B006266CBQ37568863-EF12694A-E4EF-4412-A267-953AA0003EBBQ37598881-2EF733F5-ECFE-4999-B0BB-E5E51B5453DCQ37653125-FB3AB6BB-BF20-4942-A929-C426367A65B1
P2860
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@en
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@nl
type
label
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@en
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@nl
prefLabel
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@en
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@nl
P2093
P921
P1476
Effect of saxagliptin as add-o ...... sulin combined with metformin.
@en
P2093
Anthony H Barnett
Bernard Charbonnel
Douglas Fleming
Mark Donovan
Roland Chen
P304
P356
10.1185/03007995.2012.665046
P407
P577
2012-03-01T00:00:00Z